PRC
CBAY

Pearl River Capital’s Cymabay Therapeutics CBAY Stock Holding History

Pearl River Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,400
Closed -$74K – 871
2018
Q4 		$74K Buy
+9,400
New +$89.5K 0.34% 76

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Pearl River Capital's CBAY Position: Q1 2019 in Review

Pearl River Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2019, closing a stake of 9,400 shares — an estimated $74K sold.

Pearl River Capital first reported a position in CBAY in Q4 2018 and held it in 1 quarter. The position peaked at $74K in Q4 2018. 143 funds tracked by Wall St. Rank hold CBAY as of Q1 2019.

  • Pearl River Capital reported no remaining Cymabay Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 9,400 Cymabay Therapeutics shares in Q1 2019, an estimated $74K.
  • Pearl River Capital first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Cymabay Therapeutics position peaked at $74K in Q4 2018.
  • 143 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.